Comparison of inflammatory and behavioral responses to chronic stress in female and male mice.
(+)-Naloxone
Depression
Inflammation
Microbiome
Sex differences
Toll-like receptor-4
Journal
Brain, behavior, and immunity
ISSN: 1090-2139
Titre abrégé: Brain Behav Immun
Pays: Netherlands
ID NLM: 8800478
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
17
05
2022
revised:
26
08
2022
accepted:
29
08
2022
pubmed:
5
9
2022
medline:
14
10
2022
entrez:
4
9
2022
Statut:
ppublish
Résumé
Major depressive disorder (MDD) is a debilitating disease with a high worldwide prevalence. Despite its greater prevalence in women, male animals are used in most preclinical studies of depression even though there are many sex differences in key components of depression, such as stress responses and immune system functions. In the present study, we found that chronic restraint stress-induced depressive-like behaviors are quite similar in male and female mice, with both sexes displaying increased immobility time in the tail suspension test and reduced social interactions, and both sexes exhibited deficits in working and spatial memories. However, in contrast to the similar depressive-like behaviors developed by male and female mice in response to stress, they displayed different patterns of pro-inflammatory cytokine increases in the periphery and the brain, different changes in microglia, and different changes in the expression of Toll-like receptor 4 in response to stress. Treatment with (+)-naloxone, a Toll-like receptor 4 antagonist that previously demonstrated anti-depressant-like effects in male mice, was more efficacious in male than female mice in reducing the deleterious effects of stress, and its effects were not microbiome-mediated. Altogether, these results suggest differential mechanisms to consider in potential sex-specific treatments of depression.
Identifiants
pubmed: 36058417
pii: S0889-1591(22)00373-7
doi: 10.1016/j.bbi.2022.08.017
pmc: PMC9561002
mid: NIHMS1835375
pii:
doi:
Substances chimiques
Cytokines
0
Toll-Like Receptor 4
0
Naloxone
36B82AMQ7N
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
180-197Subventions
Organisme : BLRD VA
ID : I01 BX003678
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH104656
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH110415
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Semin Cell Dev Biol. 2017 Jan;61:92-98
pubmed: 27375045
Neuropharmacology. 2018 Mar 1;130:30-41
pubmed: 29175352
J Neuroinflammation. 2019 Mar 1;16(1):53
pubmed: 30823925
Arch Gen Psychiatry. 2005 Jun;62(6):617-27
pubmed: 15939839
Trends Neurosci. 2015 Oct;38(10):637-658
pubmed: 26442697
Genes Brain Behav. 2016 Mar;15(3):348-55
pubmed: 26749572
Biol Psychiatry. 2016 Sep 15;80(6):448-456
pubmed: 26957131
PLoS One. 2011 Mar 21;6(3):e17996
pubmed: 21445311
Nat Rev Neurosci. 2008 Jan;9(1):46-56
pubmed: 18073775
Neurosci Biobehav Rev. 2016 Oct;69:313-32
pubmed: 27395342
Neuropsychopharmacology. 2018 May;43(6):1276-1283
pubmed: 29090682
Brain Behav Immun. 2020 Oct;89:51-58
pubmed: 32479995
Brain Behav Immun. 2016 Mar;53:207-222
pubmed: 26772151
Anesth Analg. 2003 Nov;97(5):1464-1468
pubmed: 14570666
J Psychiatr Res. 2003 May-Jun;37(3):249-59
pubmed: 12650744
Neuro Endocrinol Lett. 2017 Feb;38(1):19-26
pubmed: 28456144
Sci Immunol. 2018 Jan 26;3(19):
pubmed: 29374079
Front Immunol. 2017 Jun 30;8:754
pubmed: 28713378
Neurochem Res. 2017 Oct;42(10):2698-2711
pubmed: 28434164
Brain Behav Immun. 2016 Feb;52:88-97
pubmed: 26441134
Endocrinology. 2009 Aug;150(8):3877-84
pubmed: 19406943
Neuropsychopharmacology. 2008 Apr;33(5):1038-48
pubmed: 17593929
Am J Psychiatry. 2020 Oct 1;177(10):974-990
pubmed: 32731813
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8514-9
pubmed: 12824464
Sci Rep. 2017 Oct 9;7(1):12838
pubmed: 28993631
Neuropharmacology. 2018 Jun;135:223-233
pubmed: 29574097
J Neuroinflammation. 2022 Jun 6;19(1):132
pubmed: 35668399
Biol Psychiatry. 2009 Jul 1;66(1):84-90
pubmed: 19358977
Exp Clin Psychopharmacol. 2017 Apr;25(2):74-83
pubmed: 28287791
PLoS One. 2016 Sep 15;11(9):e0162971
pubmed: 27631979
Neuroscience. 2015 Apr 2;290:49-60
pubmed: 25595985
Neurosci Biobehav Rev. 2015 Dec;59:111-40
pubmed: 26475995
Brain Behav Immun. 2020 Nov;90:226-234
pubmed: 32860941
Nat Rev Neurosci. 2005 Jun;6(6):463-75
pubmed: 15891777
Neuropsychopharmacology. 2008 Jun;33(7):1559-69
pubmed: 17712351
Neurobiol Stress. 2021 Mar 04;14:100312
pubmed: 33748354
Pharmacol Biochem Behav. 1989 Sep;34(1):119-27
pubmed: 2626443
Mol Psychiatry. 2020 Nov;25(11):2759-2772
pubmed: 32332994
Biol Psychiatry. 2019 Mar 15;85(6):443-453
pubmed: 30470559
Front Cell Neurosci. 2018 Sep 19;12:294
pubmed: 30283302
Front Neurosci. 2018 Aug 17;12:547
pubmed: 30174579
Mol Psychiatry. 2022 Apr;27(4):1920-1935
pubmed: 35194166
Neurobiol Stress. 2017 Mar 19;7:124-136
pubmed: 29276734
Front Cell Neurosci. 2018 Oct 16;12:306
pubmed: 30459555
Sci Signal. 2010 Oct 12;3(143):ra74
pubmed: 20940427
Behav Brain Res. 2020 Apr 6;383:112519
pubmed: 32006567
Brain Behav Immun. 2018 Jan;67:1-12
pubmed: 28216088
Am J Pathol. 1963 Apr;42:471-83
pubmed: 13966929
Neurosci Biobehav Rev. 2005;29(4-5):571-625
pubmed: 15890404
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Biol Reprod. 2008 Mar;78(3):432-7
pubmed: 18003947
Brain Res. 1998 Jun 15;796(1-2):315-8
pubmed: 9689486
Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6325-30
pubmed: 22474354
Acta Neuropathol. 2014 Jan;127(1):109-35
pubmed: 24318124
J Neuroinflammation. 2021 Nov 6;18(1):258
pubmed: 34742308
Biol Psychiatry. 2013 Apr 1;73(7):622-30
pubmed: 23174342
Mol Psychiatry. 2014 Jun;19(6):699-709
pubmed: 24342992
Science. 2012 Oct 5;338(6103):68-72
pubmed: 23042884
Brain Res. 2001 Jun 22;904(2):279-89
pubmed: 11406126
PLoS One. 2019 Apr 15;14(4):e0215554
pubmed: 30986274
Int J Neuropsychopharmacol. 2008 Jun;11(4):577-8; author reply 579-82
pubmed: 18419849
Front Neurosci. 2014 Sep 30;8:309
pubmed: 25324715
Nat Neurosci. 2019 Jul;22(7):1046-1052
pubmed: 31182869
Nat Neurosci. 2015 Oct;18(10):1386-93
pubmed: 26404713
Neuropharmacology. 2013 Jul;70:27-34
pubmed: 23337256
J Neuroinflammation. 2019 Jul 18;16(1):148
pubmed: 31319868
PLoS One. 2011 Feb 25;6(2):e17405
pubmed: 21364768
J Physiol. 2004 Jul 1;558(Pt 1):263-75
pubmed: 15133062
Nat Commun. 2015 Jul 28;6:7735
pubmed: 26218677
J Neurosci. 2015 Dec 16;35(50):16362-76
pubmed: 26674863
Neurosci Biobehav Rev. 2011 Jan;35(3):565-72
pubmed: 20620164
Nat Commun. 2020 Dec 11;11(1):6363
pubmed: 33311466
Sci Rep. 2015 Mar 26;5:9499
pubmed: 25962524
Brain Behav Immun. 2016 Aug;56:140-55
pubmed: 26923630
Br J Pharmacol. 2016 Mar;173(5):856-69
pubmed: 26603732
Nat Rev Microbiol. 2019 Apr;17(4):196
pubmed: 30760901
ILAR J. 2014;55(2):221-32
pubmed: 25225302
Neuropsychopharmacology. 2004 May;29(5):952-9
pubmed: 14997169
Curr Top Behav Neurosci. 2017;31:155-172
pubmed: 27352390
Transl Psychiatry. 2020 Sep 11;10(1):310
pubmed: 32917850
J Neuroinflammation. 2019 Dec 17;16(1):266
pubmed: 31847911